|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For each participating company, this section presents a detailed summary highlighting their core technologies, capabilities, technologies, and services.
|
|
|
Jim Huang, PhD, says a thorough understanding of their amorphous stabilization and nano colloidal properties in relationship to in-vitro and in-vivo performance will help advance this interesting dosage form into human clinical testing and commercialization.
|
|
|
Rupa Doshi, PhD, and Sameena Sharif, PhD, explore the landscape of rare cancer clinical trials, from key considerations for study design and the value of biomarkers to the importance of the patient perspective and the options for speeding much-needed therapies to market.
|
|
|
David Bunka, PhD, and Emily Robinson, PhD, focus on a new breed of affinity binders that can be used as an alternative to antibody therapeutics and has the potential to reshape the industry, delivering new medicines with improved safety and efficacy profiles and reduced healthcare costs.
|
|
|
|
|
|
|
|
|

Kymanox is a life science professional services organization that offers engineering, scientific, and compliance support to companies exclusively in the biotechnology, pharmaceutical, medical device, and combination product industries. With its diverse team, Kymanox helps clients navigate commercialization challenges that arise throughout a product’s lifecycle – from early development to post-market commercialization – with optimized safety, quality, efficacy, and accessibility. Click here for more.
|
|
|
|
|
|
 |
|
Adare Pharma Solutions recently announced the acquisition of Frontida BioPharm, a vertically integrated CDMO focused on oral formulations. The acquisition reinforces….
|
|
 |
|
Sterling Pharma Solutions recently announced an exclusive partnership with the University of Manchester Institute of Biotechnology (MIB), to support the development of a novel, low-cost manufacturing route to molnupiravir, a new….
|
|
 |
|
SAB Biotherapeutics recently announced that SAB-176, its investigational therapeutic for the treatment of seasonal influenza, achieved statistically significant (p = 0.026) reductions in viral load and….
|
|
 |
|
BioXcel Therapeutics, Inc. recently announced the US FDA has extended the Prescription Drug User Fee Act (PDUFA) date for its review of the New Drug Application (NDA) of BXCL501 for the acute treatment of….
|
|
 |
|
Akoya Biosciences, Inc., The Spatial Biology Company, recently announced its Advanced Biopharma Solutions (ABS) laboratory, located in Marlborough, MA, has received its Certificate of Registration from the….
|
|
|
|
|
Upcoming eNewsletter Features:
December 15 – Nasal Drug Delivery
January 5 – Capsules
|
|
|
|
|
|
|
|